[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 41 of about 41
1. Geller JI, Argani P, Adeniran A, Hampton E, De Marzo A, Hicks J, Collins MH: Translocation renal cell carcinoma: lack of negative impact due to lymph node spread. Cancer; 2008 Apr 1;112(7):1607-16
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translocation renal cell carcinoma: lack of negative impact due to lymph node spread.
  • BACKGROUND: Pediatric renal cell carcinoma (RCC) is clinically distinct from adult RCC.
  • RESULTS: Eleven cases of RCC with clinical data were identified in our institutional review as follows: 6 clear cell, 2 papillary, 2 translocation, and 1 sarcomatoid.
  • Seven of 8 TFE+ RCC patients presented with TNM Stage III/IV disease.
  • Literature analysis confirmed a significant increase in advanced stage presentation in pediatric TFE+ RCC compared with TFE- RCC.
  • Fourteen of fifteen (93.3%) patients with TFE+ stage III/IV RCC due to lymph node spread (N+ M(0)) remain disease free with a median and mean follow-up of 4.4 and 6.3 years, respectively (range, 0.3-15.5).
  • CONCLUSIONS: Translocation morphology RCC is the predominant form of pediatric RCC, associated with an advanced stage at presentation.
  • Young RCC patients should be screened for translocation morphology, and the screening information should be considered when debating adjuvant therapy.
  • [MeSH-major] Carcinoma, Renal Cell / genetics. Kidney Neoplasms / genetics. Kidney Neoplasms / pathology. Lymph Nodes / pathology. Translocation, Genetic
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / secondary. Adolescent. Basic Helix-Loop-Helix Leucine Zipper Transcription Factors / genetics. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / genetics. Carcinoma, Papillary / secondary. Child. Cohort Studies. Female. Follow-Up Studies. Humans. Immunoenzyme Techniques. Leucine Zippers. Lymphatic Metastasis. Male. Microphthalmia-Associated Transcription Factor / genetics. Neoplasm Proteins / genetics. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18278810.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; 0 / MITF protein, human; 0 / Microphthalmia-Associated Transcription Factor; 0 / Neoplasm Proteins; 0 / TFE3 protein, human; 0 / TFEB protein, human
  •  go-up   go-down


2. Yamamoto S, Ito T, Akiyama A, Miki M, Tachibana M, Takase M, Matsumoto T, Mochizuki M: Primary signet-ring cell carcinoma of the urinary bladder inducing renal failure. Int J Urol; 2001 Apr;8(4):190-3
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary signet-ring cell carcinoma of the urinary bladder inducing renal failure.
  • A case of primary signet-ring cell carcinoma of the urinary bladder that was found to have induced renal failure is the second such case reported in the world.
  • Primary signet-ring cell carcinoma of the urinary bladder is a rare histologic variant of adenocarcinoma.
  • The neoplasm had a high stage at diagnosis, so the prognosis was very poor.
  • To improve the prognosis, earlier diagnosis and establishing a regimen of chemotherapy is necessary.
  • [MeSH-major] Carcinoma, Signet Ring Cell / complications. Renal Insufficiency / etiology. Urinary Bladder Neoplasms / complications

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11260353.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 12
  •  go-up   go-down


3. Kyan A, Kato SN: [Renal cell carcinoma metastatic to the base of tongue: a case report]. Hinyokika Kiyo; 2004 Nov;50(11):791-3
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Renal cell carcinoma metastatic to the base of tongue: a case report].
  • A 66-year-old male patient underwent left radical nephrectomy for stage III renal cell carcinoma (RCC) two years and eight months previously.
  • It was pathologically diagnosed as clear cell carcinoma and as tongue metastasis of RCC.
  • At present, two years after the treatment, neither growth of lung metastasis nor recurrence of tongue tumor are noticed.
  • [MeSH-major] Adenocarcinoma, Clear Cell / surgery. Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology. Neoplasms, Multiple Primary. Tongue Neoplasms / secondary
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Humans. Interferon-alpha / therapeutic use. Interleukin-2 / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Neoplasm Staging. Nephrectomy. Treatment Outcome

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15628540.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Interleukin-2
  • [Number-of-references] 18
  •  go-up   go-down


Advertisement
4. Punushapai U, Yuenyao P, Chumworathayi B, Luanratanakorn S, Udomthavornsuk B: Weekly cisplatin 20 mg/m2 in patients with carcinoma of cervix receiving pelvic radiotherapy at Srinagarind Hospital: a randomized controlled trial. Asian Pac J Cancer Prev; 2010;11(1):201-7
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To evaluate treatment response and acute treatment-related toxicity of concurrent chemoradiotherapy with cisplatin 20 mg/m2 , compared to 40 mg/m2 as the standard, in locally advanced cervical cancer.
  • SUBJECTS: 140 patients, >60 years old with biopsy-proven previously untreated invasive carcinoma of cervix, FIGO stage IB2-IVA, undergoing concurrent chemoradiotherapy with adequate bone marrow, renal and liver functions, between April and December 2009.
  • Main outcome measures included clinical response, cytological response, and acute treatment-related toxicity.
  • 80% had squamous cell carcinomas; about half were FIGO stage IIIB.
  • The 40 mg/m2 group showed unplanned interruptions in 13/70 (18.6%), which was significantly different from the 5/70 (7.1%) in the 20 mg/m2 group (p=0.02), resulting in prolonged treatment time (p=0.026).
  • No treatment related deaths were encountered.
  • CONCLUSION: This prospective trial has sufficient data to support the conclusion that concurrent chemoradiotherapy with weekly cisplatin 40 mg/m2 in locally advanced cervical cancer gives good treatment outcomes.
  • When reducing the cisplatin dose to 20 mg/m2, treatment responses were still comparable to the standard, but acute toxicity could be reduced.
  • However, there are insufficient data to assess long term treatment outcomes and late treatment related toxicity, because of the short follow-up time.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Pelvic Neoplasms / drug therapy. Pelvic Neoplasms / radiotherapy. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Combined Modality Therapy. Female. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prospective Studies. Radiotherapy Dosage. Survival Rate. Treatment Outcome


5. Negi RR, Gupta M, Kumar M, Gupta MK, Seam R, Rastogi M: Concurrent chemoradiation in locally advanced carcinoma cervix patients. J Cancer Res Ther; 2010 Apr-Jun;6(2):159-66
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 31st 2006, 102 patients of carcinoma cervix belonging to stage IIA to IV A were enrolled in the study.
  • External beam radiation therapy was administered using Cobalt 60 teletherapy machine.
  • Cisplatinum (40 mg/m 2) and 5 Fluorouracil (500 mg/m 2 ) continuous infusions with radiotherapy on D2-D5 in first and last 5 # of radiation therapy were administered.
  • RESULTS: Response to treatment and toxicities were monitored and analyzed in 102 patients (50 study group and 52 control group).
  • All 102 patients completed treatment.
  • No difference in overall renal, hematological and cutaneous toxicity was seen between two groups.
  • This could be due to more bulk of tumor stage per stage, poor nutritional status, less number of patients in both arms, not enough to pick up statistically significant small difference in outcome.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cobalt Radioisotopes / therapeutic use. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adult. Aged. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / administration & dosage. Combined Modality Therapy. Feasibility Studies. Female. Fluorouracil / administration & dosage. Humans. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20622362.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Cobalt Radioisotopes; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


6. Silva RG, Dahmoush L, Gerke H: Pancreatic metastasis of an ovarian malignant mixed Mullerian tumor identified by EUS-guided fine needle aspiration and Trucut needle biopsy. JOP; 2006;7(1):66-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE REPORT: We describe a 69-year-old female with concomitant Duke's C adenocarcinoma of the colon and stage III-C malignant mixed Mullerian tumor that presented with malignant ascites, increasing abdominal girth and a pancreatic head mass.
  • The patient was treated with palliative chemotherapy and a three-month follow up CT scan did not reveal any new metastatic lesions.
  • CONCLUSION: The pancreas is a rare site of metastasis and more commonly seen in renal cell carcinoma, melanoma or lung tumors; amongst others.
  • Although ovarian adenocarcinoma has been reported as a primary site of pancreatic metastasis, it has not been previously described originating from a mixed Mullerian tumor of the ovary presenting as a cystic pancreatic head mass.
  • [MeSH-minor] Aged. Biopsy, Fine-Needle / methods. Endosonography. Female. Humans. Neoplasm Staging. Pancreas / pathology. Pancreas / radiography. Prognosis. Tomography, X-Ray Computed


7. Kamiński B, Kobiorska-Nowak J, Bień S: [Distant metastases to nasal cavities and paranasal sinuses, from the organs outside the head and neck]. Otolaryngol Pol; 2008;62(4):422-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At that time, the correct diagnosis requires only to compare the pathology report from the primary biopsy, with the biopsy from the lump in the head and neck.
  • The palliative Rtg-therapy was applied, and patient died in 2 months after diagnosis was established.
  • Case II. M. 69 y with metastasis of kidney cancer (Ca clarocellulare) to the nasal cavity, during a palliative stage of the disease due to multiple lung metastases.
  • Patient was treated with multiple courses of chemotherapy due to generalization of the disease.
  • Cases III. F. 50 years in palliative stage of the breast cancer, with metastases to the bones and hepar and with metastasis to the maxillary sinus.
  • Received palliative Rtg. therapy on the region of metastasis.
  • Case IV. F. 54 years in palliative stage of the colonic cancer, with multiple metastases to the lungs and hepar; with metastasis to the maxillary sinus.
  • The palliative Rtg-therapy on the region of metastasis.
  • In the majority of distant metastases to the nose and paranasal sinuses, the palliative therapy is the only possible option of treatment.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Carcinoma, Renal Cell / pathology. Colonic Neoplasms / pathology. Paranasal Sinus Neoplasms / secondary. Skull Base Neoplasms / secondary
  • [MeSH-minor] Aged. Female. Humans. Male. Middle Aged. Poland. Prognosis. Survival Analysis. Treatment Failure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18837216.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


8. Safranek PM, Sujendran V, Baron R, Warner N, Blesing C, Maynard ND: Oxford experience with neoadjuvant chemotherapy and surgical resection for esophageal adenocarcinomas and squamous cell tumors. Dis Esophagus; 2008;21(3):201-6
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxford experience with neoadjuvant chemotherapy and surgical resection for esophageal adenocarcinomas and squamous cell tumors.
  • The Medical Research Council trial for oesophageal cancer (OEO2) trial demonstrated a clear survival benefit from neoadjuvant chemotherapy in resectable esophageal carcinoma.
  • Since February 2000 it has been our practice to offer this chemotherapy regime to patients with T2 and T3 or T1N1 tumors.
  • We analyzed prospectively collected data of patients who received neoadjuvant chemotherapy prior to esophageal resection under the care of a single surgeon.
  • Complications of treatment and overall outcomes were evaluated.
  • During chemotherapy one patient died and one perforated (operated immediately).
  • Complications including severe neutropenia, coronary artery spasm, renal impairment and pulmonary edema led to the premature cessation of chemotherapy in 12 patients (6.2%).
  • A total of 182 patients with a median age of 63 (range 30-80), 41 squamous and 141 adenocarcinomas underwent surgery.
  • Operations were 91 left thoracoabdominal (50%), 45 radical transhiatal (25%), 40 Ivor-Lewis (22%) and six stage three (3%), and 78.6% had microscopically complete (R0) resections.
  • A radical surgical approach to the primary tumor in combination with OEO2 neoadjuvant chemotherapy has led to a high R0 resection rate and good survival with acceptable morbidity and mortality.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18430099.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Rauh-Hain JA, Penson RT: Potential benefit of Sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma. Int J Gynecol Cancer; 2008 Sep-Oct;18(5):934-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential benefit of Sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma.
  • Ovarian clear cell adenocarcinoma (OCCA) is a unique biological subtype of epithelial ovarian cancer, with a similar gene profile to renal cell carcinoma (RCC).
  • Sunitinib is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with proven antitumor activity in RCC and a rational biological option for treatment of OCCA.
  • A 60-year-old woman presented with recurrent and refractory stage IA OCCA, after 9 years of remission.
  • Sunitinib was initiated as fifth-line chemotherapy, associated with cystic degeneration of liver metastasis and a short downward trend in her CA125 level.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Antineoplastic Agents / therapeutic use. Indoles / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy. Pyrroles / therapeutic use
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18081793.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Indoles; 0 / Pyrroles; 0 / sunitinib
  •  go-up   go-down


10. Kocak M, Mayadagli A, Ozkan A, Parlak C, Demir O, Marti A, Dogan Eren M, Kaya S, Gumus M: Outcome of metastatic non-small cell lung carcinoma patients receiving docetaxelcisplatin combination chemotherapy: single institution experience. J BUON; 2007 Oct-Dec;12(4):471-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of metastatic non-small cell lung carcinoma patients receiving docetaxelcisplatin combination chemotherapy: single institution experience.
  • PURPOSE: Despite advances in the detection and treatment, the long-term survival of patients with advanced nonsmall cell lung cancer (NSCLC) remains poor, with a 5-year overall survival (OS) of less than 5%.
  • We conducted this observational study to determine the influence of docetaxel plus cisplatin combination chemotherapy on response, time to progression (TTP) and OS, and to evaluate its tolerability in chemotherapy-naïve patients with metastatic NSCLC.
  • PATIENTS AND METHODS: Patients with histologically or cytologically confirmed stage IV NSCLC who met the following criteria were eligible for the study: no previous chemotherapy, Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2, objectively measurable disease, adequate bone marrow reserve, normal hepatic and renal function.
  • Median follow-up time was 6 months (range 1-21).
  • Histological type was squamous cell carcinoma in 21 (42%) patients, adenocarcinoma in 11 (22%) and undifferentiated carcinoma in 18 (36%).
  • The median OS time was 16 months (range 7.1-24.9; 95% CI: 8-24).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Cisplatin / administration & dosage. Lung Neoplasms / drug therapy. Taxoids / administration & dosage
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18067204.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. Kim YH, Kim JS, Choi YH, In KH, Park HS, Hong DS, Jeong TJ, Lee YY, Nam E, Lee SN, Lee KS, Kim HK: Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non-small-cell lung cancer. Int J Clin Oncol; 2002 Apr;7(2):114-9
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non-small-cell lung cancer.
  • BACKGROUND: Docetaxel is highly active in the second-line treatment of patients with metastatic or unresectable locally advanced nonsmall-cell lung cancer (NSCLC).
  • As there is a need for first-line chemotherapy that is more effective than standard platinum-based chemotherapy, this study was undertaken to evaluate the efficacy and tolerability of a docetaxel/cisplatin combination as first-line chemotherapy in advanced NSCLC.
  • METHODS: Newly diagnosed, chemotherapy-naive patients with histologically confirmed NSCLC (measurable stage IIIB/IV NSCLC; Karnofsky performance status, 70-100; adequate bone marrow, renal, hepatic, and cardiac function) were eligible for the study.
  • Histologically, 23 patients (59%) had adenocarcinoma, 12 (30.8%) had squamous cell carcinoma, and 16 patients (41%) had stage IV disease.
  • Median overall survival time in all eligible patients was 10.5 months.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Paclitaxel / analogs & derivatives. Taxoids
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Female. Hematologic Diseases / chemically induced. Humans. Infusions, Intravenous. Male. Middle Aged. Survival Rate. Treatment Outcome


12. Cobo Dols M, Villar Chamorro E, Alés Díaz I, Gil Calle S, Alcalde García J, Gutiérrez Calderón V, Carabantes Ocón F, Montesa Pino A, Bretón García JJ, Benavides Orgaz M: Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy. Clin Transl Oncol; 2006 Oct;8(10):742-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
  • Objective. We conducted this phase II trial to evaluate the efficacy and toxicity of the sequential nonplatinum combination chemotherapy consisting of gemcitabine (GEM) and vinorelbine (VNR) followed by weekly docetaxel (DOC) in patients with advanced non-small-cell lung cancer (NSCLC).
  • ELIGIBILITY CRITERIA: stage IV NSCLC, Performance status =/< 2, adequate renal, hepatic and bone marrow function.
  • Treatment consisted on: VNR 25 mg/m(2) plus gemcitabine 1000 mg/m(2), on days 1 and 8 of each 21-day cycle, followed by docetaxel 36 mg/m(2) weekly until progression or unacceptable toxicity.
  • Results. 21 stage IV patients were enrolled.
  • All patients are evaluable for treatment response and toxicity profile.
  • Histology types were: adenocarcinoma in 8 patients (38%), large cell carcinoma in 1 patients (5%) and squamous cell carcinoma in 12 patients (57%).
  • The median number of cycles of gemcitabine-navelbine was 4 (range 2-6) Of the 13 patients (61%) who completed six cycles of gemcitabine-navelbine, all of them went on to receive weekly docetaxel and received at least 3 cycles, with a median number of 8 cycles (range 3- 16).
  • The median survival time (MST) was 7.9 months, and the 1-year survival was 30%, and the median progression-free survival was 4.7 months.
  • Nonhematologic toxicity was also mild: 1 patient with Grade 3 skin toxicity with docetaxel, 1 patient with grade 3 infection, 2 patients with grade 3 astenia and 1 patient with a mild allergic reaction postchemotherapy treatment with docetaxel.
  • Conclusion. The sequential triplet nonplatinum chemotherapy consisted of GEM/VNR followed by weekly DOC is active and can be administered safely in advanced NSCLC.
  • Our results are similar with other sequential regimens and did not represent a significant improvement in the treatment of this disease.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Deoxycytidine / analogs & derivatives. Lung Neoplasms / drug therapy. Taxoids / administration & dosage. Vinblastine / analogs & derivatives
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Aged. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Female. Follow-Up Studies. Humans. Lung / pathology. Male. Middle Aged. Neoplasm Staging. Survival Analysis. Time Factors

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2005 Jan;16(1):97-101 [15598945.001]
  • [Cites] Lung Cancer. 2001 Nov;34(2):271-7 [11679186.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):557-62 [10649247.001]
  • [Cites] Lung Cancer. 2005 Aug;49(2):233-40 [16022917.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3207-13 [12947054.001]
  • [Cites] Chest. 2000 Jun;117(6):1583-9 [10858387.001]
  • [Cites] Br J Cancer. 2003 Feb 10;88(3):342-7 [12569374.001]
  • [Cites] Cancer. 2000 Aug 15;89(4):763-8 [10951338.001]
  • [Cites] Lung Cancer. 2005 Feb;47(2):269-75 [15639726.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):330-53 [14691125.001]
  • [Cites] Lung Cancer. 2005 Dec;50(3):355-74 [16139391.001]
  • [Cites] Lung Cancer. 2001 Oct;34(1):115-23 [11557121.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1318-25 [14977831.001]
  • [Cites] Cancer Res. 1986 Aug;46(8):3876-85 [3731062.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5022-6 [15297403.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2095-103 [10811675.001]
  • [Cites] Invest New Drugs. 2006 May;24(3):241-8 [16096704.001]
  • [Cites] Ann Oncol. 2000 Aug;11(8):993-8 [11038036.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1866-72 [8410111.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):146-52 [11443620.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2348-56 [15197195.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(12):2354-62 [10856094.001]
  • [Cites] J Natl Cancer Inst. 2003 Mar 5;95(5):362-72 [12618501.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):92-8 [11784875.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3025-34 [12837810.001]
  • [Cites] Eur J Cancer. 2001 Mar;37(5):583-90 [11290433.001]
  • [Cites] Lung Cancer. 2004 Jan;43(1):93-100 [14698543.001]
  • [Cites] BMJ. 1995 Oct 7;311(7010):899-909 [7580546.001]
  • [Cites] Oncology. 2005;68(4-6):382-90 [16020967.001]
  • [Cites] Clin Lung Cancer. 1999 Nov;1(2):122-7; discussion 128-9 [14733660.001]
  • [Cites] Lung Cancer. 2005 Sep;49(3):289-98 [15913840.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2529-36 [10893283.001]
  • [Cites] Clin Cancer Res. 1998 May;4(5):1087-100 [9607565.001]
  • [Cites] Ann Oncol. 1999 Sep;10(9):1059-63 [10572603.001]
  • [Cites] Cancer Res. 1984 Sep;44(9):3643-53 [6744284.001]
  • (PMID = 17074673.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; Q6C979R91Y / vinorelbine
  •  go-up   go-down


13. Lin CM, Chen CH, Chang JW, Tsao TC: Phase II study of epirubicin in combination with weekly docetaxel for patients with advanced NSCLC who have failed or relapsed after the frontline platinum-based chemotherapy. Am J Clin Oncol; 2009 Apr;32(2):169-73
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of epirubicin in combination with weekly docetaxel for patients with advanced NSCLC who have failed or relapsed after the frontline platinum-based chemotherapy.
  • BACKGROUND: We conducted a phase II study to evaluate the efficacy and toxicity of weekly docetaxel combined with epirubicin on D15 as second-line chemotherapy in Taiwanese patients with advanced non small cell lung cancer (NSCLC) who failed or relapsed after the frontline platinum-based chemotherapy.
  • PATIENTS AND METHODS: Patients with histologically confirmed advanced NSCLC (Stage IIIB-IV) were entered into this Phase II trial.
  • Treatment was repeated every 4 weeks for a maximal total of 6 cycles.
  • The median time to disease progression for all patients was 2.8 months (95% CI 1.3-4.3%).
  • The median survival time for all patients was 7.7 months (95% CI 5.5-9.9%).
  • Hepatic and renal impairment was also only mild.
  • CONCLUSION: Combining weekly doses of docetaxel 30 mg/m with epirubicin 60 mg/m on D15 was not shown to improve both efficacy and tolerability for advanced NSCLC patients who have relapsed disease after frontline platinum-based chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Squamous Cell / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Epirubicin / administration & dosage. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Staging. Prognosis. Salvage Therapy. Survival Rate. Taxoids / administration & dosage. Treatment Failure

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19307958.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; 3Z8479ZZ5X / Epirubicin
  •  go-up   go-down


14. Nagao S, Fujiwara K, Oda T, Ishikawa H, Koike H, Tanaka H, Kohno I: Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer. A pilot study. Gynecol Oncol; 2005 Mar;96(3):805-9
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer. A pilot study.
  • OBJECTIVES: This is a pilot study for a future trial to assess the efficacy and safety of combination chemotherapy with docetaxel and carboplatin in advanced or recurrent uterine cervix cancer.
  • METHODS: The patients eligible for this study had histologically confirmed, advanced (stage IB2-IV) or recurrent uterine cervix cancer.
  • Eligible patients had measurable lesions and must have sufficient bone marrow, renal, and liver functions.
  • Chemotherapy was repeated in 1-6 courses depending on the purpose of the therapy.
  • The distribution of stage was IB2, 3; IIB, 8; IIIB, 3; IVB, 1; recurrent, 2.
  • There were 9 squamous cell carcinomas, 6 adenocarcinomas, 1 adenosquamous cell carcinoma, and 1 small cell carcinoma.
  • All 5 adenocarcinoma patients in the neoadjuvant chemotherapy group responded including 1 pathological CR.
  • CONCLUSIONS: The combination of docetaxel and carboplatin is an effective and safe treatment for uterine cervix cancer.
  • Further evaluation particularly targeted on cervical adenocarcinoma is warranted.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Carboplatin / adverse effects. Female. Humans. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Pilot Projects. Taxoids / administration & dosage. Taxoids / adverse effects

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15721429.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin
  •  go-up   go-down


15. Hashimoto H, Oshika Y, Obara K, Tanaka Y, Shimizu E: [A dialysis patient with advanced lung adenocarcinoma who was safely given biweekly gemcitabine therapy]. Gan To Kagaku Ryoho; 2010 Aug;37(8):1553-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A dialysis patient with advanced lung adenocarcinoma who was safely given biweekly gemcitabine therapy].
  • BACKGROUND: Although the number of advanced lung cancer patients on hemodialysis is expected to increase in the future, there has been no established treatment regimen yet.
  • We report our experience with gemcitabine safely administered to an elderly patient requiring hemodialysis who had advanced lung adenocarcinoma.
  • CASE: A 87-year-old man had been on dialysis for chronic renal failure.
  • A diagnosis of Stage IIIB lung adenocarcinoma was made based on the findings of cytology from the pleural effusions and radiological examinations.
  • After intrapleural cisplatin administration, he was given outpatient chemotherapy.
  • CONCLUSION: We described a dialysis patient with advanced non-small cell lung cancer who was given biweekly gemcitabine for 20 months.
  • [MeSH-major] Adenocarcinoma / drug therapy. Deoxycytidine / analogs & derivatives. Kidney Failure, Chronic / therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Aged, 80 and over. Humans. Male. Neoplasm Staging. Renal Dialysis

  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20716885.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


16. Chitapanarux I, Tonusin A, Sukthomya V, Charuchinda C, Pukanhapan N, Lorvidhaya V: Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer. Gynecol Oncol; 2003 Jun;89(3):402-7
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer.
  • OBJECTIVE: The goal of this study was to evaluate the efficacy and tolerability of irinotecan plus cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer.
  • METHODS: Chemotherapy-naive patients with metastatic or recurrent disease and at least one measurable tumor site received irinotecan (60 mg/m(2) IV infusion over 90 min) on Days 1, 8, and 15, followed by cisplatin (60 mg/m(2) IV over 90 min) on Day 1, every 28 days for a maximum of six cycles.
  • Seven patients were stage IVB at diagnosis.
  • Median time to relapse was 13.4 months, with a median survival time of 16.9 months.
  • Dose-limiting toxicity was observed in 4 patients (13.3%) with grade 3 renal toxicity.
  • Nine patients (30%) developed grade 3 neutropenia, and only grade 1-2 acute and late diarrhea were observed in 20 and 40%, respectively.
  • A patient developed pancolitis after the sixth cycle.
  • There were no chemotherapy-related deaths.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Carcinoma, Squamous Cell / drug therapy. Neoplasm Recurrence, Local / drug therapy. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Cisplatin / adverse effects. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Infusions, Intravenous. Middle Aged. Neoplasm Metastasis. Prospective Studies. Survival Rate


17. Parmeggiani F, Costagliola C, D'Angelo S, Incorvaia C, Perri P, Sebastiani A: Clear cell renal cell carcinoma associated with bilateral atypical acute posterior multifocal placoid pigment epitheliopathy. Oncology; 2004;66(6):502-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell renal cell carcinoma associated with bilateral atypical acute posterior multifocal placoid pigment epitheliopathy.
  • BACKGROUND/OBJECTIVE: Clear cell renal cell carcinoma (CCRCC) is a malignant neoplasm frequently associated with an increase in circulating immune complexes (CIC).
  • RESULTS: The patient underwent total left nephrectomy (May 1997) and total left pneumonectomy (March 2001) for the presence of stage III CCRCC and CCRCC lung metastasis, respectively.
  • CONCLUSIONS: Long-standing tumorous disease, through a pathogenic mechanism triggered by CIC spreading, can be responsible, over time, for a progressive choroidal occlusive microangiopathy (atypical APMPPE pattern), associated with a high risk of poor visual outcome.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Carcinoma, Renal Cell / pathology. Choroidal Neovascularization / etiology. Kidney Neoplasms / pathology. Pigment Epithelium of Eye / pathology
  • [MeSH-minor] Angiogenesis Inhibitors / therapeutic use. Antineoplastic Agents / therapeutic use. Humans. Interferon-alpha / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Male. Middle Aged. Nephrectomy. Pneumonectomy. Vision Disorders / etiology


18. Ramalingam S, Dobbs TW, Coke DE, Wojtowicz-Praga S, Belani CP: Weekly docetaxel and irinotecan for patients with advanced non-small cell lung cancer (NSCLC): Results of a multi-center, phase II study. J Clin Oncol; 2004 Jul 15;22(14_suppl):7298

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weekly docetaxel and irinotecan for patients with advanced non-small cell lung cancer (NSCLC): Results of a multi-center, phase II study.
  • : 7298 Background: The toxicity profiles of non-platinum regimens compare favorably to platinum-based combinations when used for the treatment of advanced NSCLC.
  • METHODS: Patients (N=45) with previously untreated stage IIIB (pleural or pericardial effusion)/IV NSCLC, ECOG PS < 2, normal hepatic, renal and bone marrow function were eligible.
  • RESULTS: Baseline patient characteristics were: median age 60 years (range 38-76), males - 24, stage IIIB/IV - 11/34, adenocarcinoma - 20, squamous cell carcinoma - 12, large cell carcinoma - 4, undifferentiated carcinoma - 7.
  • A total of 105 cycles of chemotherapy were administered.
  • The results are summarized below: [Figure: see text] Conclusions: The combination of docetaxel and irinotecan administered on a weekly schedule is active for first-line treatment of patients with advanced NSCLC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013635.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Gamaz M, Ameur S, Chaouche H, Bouzid K: A retrospective analysis to evaluate adjuvant chemotherapy after radical surgery on survival and disease recurrence in patients with stage I, II, IIIA non-small cell lung cancer (NSCLC). J Clin Oncol; 2004 Jul 15;22(14_suppl):7360

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective analysis to evaluate adjuvant chemotherapy after radical surgery on survival and disease recurrence in patients with stage I, II, IIIA non-small cell lung cancer (NSCLC).
  • : 7360 Background: Adjuvant chemotherapy has become a standard treatment in patients (pts) with NSCLC who have had carcinologic resection (Le Chevalier, ASCO 2003, abstr 6).
  • The aim of this retrospective study was to analyze the outcome, in terms of survival and disease recurrence, of pts with NSCLC who received adjuvant chemotherapy after radical surgery.
  • METHODS: Inclusion criteria: histologically proven NSCLC stage I-IIIA treated with carcinologic surgery, PS ≤1, and adequate hematologic, hepatic, and renal function.
  • RESULTS: Data were pooled and analyzed for 28 male pts with a median age of 54.4 years (range, 47-71 years).
  • Stage IB, IIB, and IIIA disease was noted in 7, 5, and 16 pts, respectively.
  • Histologic types were adenocarcinoma (n=11) and squamous cell carcinoma (n=17).
  • The median duration between the surgery and the onset of adjuvant chemotherapy was six weeks (range, 3-7 weeks).
  • Adjuvant chemotherapy consisted of four cycles of cisplatin (75 mg/m<sup>2</sup> d1) combined with vinblastine (6 mg/m<sup>2</sup> d1) in 2 pts, vindesine (4 mg/m<sup>2</sup> d1) in 5 pts, etoposide (150 mg/m<sup>2</sup> d1) in 7 pts, and gemcitabine (1250 mg/m<sup>2</sup> over 30 min d1,8) in 14 pts.
  • Eleven pts (with p N1 disease) received locoregional radiotherapy six weeks after the fourth cycle of chemotherapy.
  • After a median follow-up time of 28 months (range, 12-44 months), the median survival was 18 months (range, 6-43+ months).
  • The median free survival time was 16 months (range, 3-40+ months).
  • CONCLUSIONS: The results of this retrospective analysis confirm the importance of adjuvant chemotherapy in NSCLC after carcinologic resection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015086.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Massutí B, Camps C, Barceló JR, Garrido P, Viñolas N, Barneto I, Guillot M, Bover I, Jiménez M, Chaib C: Weekly paclitaxel (PCT) in non-small cell lung cancer (NSCLC): Results in older or frail patients. A Spanish Lung Cancer Group Trial (GECP 00-02). J Clin Oncol; 2004 Jul 15;22(14_suppl):8044

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weekly paclitaxel (PCT) in non-small cell lung cancer (NSCLC): Results in older or frail patients. A Spanish Lung Cancer Group Trial (GECP 00-02).
  • : 8044 Background: NSCLC patients (p) frequently older with significant comorbidities and not considered suitable for platinum-based chemotherapy (CT).
  • Weekly single-agent PCT offers potential for lower toxicity, increased exposure to the drug with alternative cytotoxic/cytostatic mechanisms.
  • METHODS: Stages IIIB (pleural effusion)-IV, > 70 y, creatinine clearance < 60 ml/min, cardiovascular diseases, stage II chronic bronchitis, untreated p, measurable disease (RECIST).
  • Treatment schedule: Paclitaxel 80 mg/m2 d1,8,15 every 28 d.
  • HISTOLOGY: Squamous (49%), Adenocarcinoma (40%).
  • Stage IV (distant metastases): 78%.
  • Comorbidities: Chronic bronchitis 41%; Heart disease 22%, Diabetes 20%, Renal disease 18%, Vascular disease 11%.
  • Median survival time (MST) 9 m with 1-year survival probability 31%; MST older 70 y 9m, younger 70 y 6 m (p= 0.08); MST PS 0-1: 11 m, PS 2-3: 6 m (p= 0.05) Toxicities: 3 p G3 anemia, 1 p G3 thrombocytopenia without bleeding, 1 p G3 neutropenia without fever; 1 p G3 arrithmia, 2 p G3 hypersensitivity, 2 p G3 neurotoxicity, 3 p G3 asthenia.
  • 23% ORR with disease control rate of 64% at 12 w in this group of p with median age 73 y, 83% Stage IV, 38% PS 2 and 49% with significant comorbidities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015856.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Casal J, Vázquez S, León L, Lázaro M, Fírvida JL, Amenedo M, Alonso G, Santomé L, Afonso FJ: Erlotinib as maintenance therapy after concurrent chemoradiotherapy in patients (p) with stage III non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):7537

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erlotinib as maintenance therapy after concurrent chemoradiotherapy in patients (p) with stage III non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group phase II study.
  • : 7537 Background: Combination of platinum-based chemotherapy and radiotherapy is the standard treatment for p with unresectable stage III NSCLC, but considering the high rates of recurrence, it is necessary to improve these results.
  • In this study, we aim to evaluate the role of erlotinib as maintenance therapy after a standard concurrent chemo-radiotherapy regimen in p with stage III NSCLC.
  • METHODS: P with unresectable stage IIIA/IIIB-without malignant effusions-NSCLC who had received a standard concurrent chemo-radiotherapy regimen and had no evidence of tumor progression were enrolled in this single arm, open-label phase II study and received erlotinib 150 mg/day po for 6 months.
  • Main eligibility criteria were: PS 0-2, adequate bone marrow, hepatic and renal function and measurable disease by RECIST criteria.
  • Primary endpoint was the percentage of p without evidence of disease progression after 6 months of erlotinib therapy and secondary endpoints were: PFS, OS, ORR and safety profile.
  • Baseline characteristics: median age 62 years (range 41-76); male 94.6%; caucasian 100%; smokers/never smokers (%) 97.3/2.7; ECOG PS 0/1/2 (%) 18.9/75.7/2.7; adenocarcinoma/squamous cell carcinoma/large cell carcinoma (%) 16.2/75.7/5.4; stage IIIA/IIIB (%) 16.2/83.8.
  • CONCLUSIONS: Erlotinib as maintenance therapy is an active and well tolerated treatment after concurrent chemo- radiotherapy in p with stage III NSCLC.
  • In spite of the majority of patients are caucasian, males, smokers with squamous cell carcinoma, maintenance with single agent erlotinib reached a promising median OS of 18.7 months.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963306.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Wozniak AJ, Kalemkerian GP, Gadgeel SM, Schneider BJ, Valdivieso M, Venkatramanamoorthy R, Hackstock DM, Chen W, Heilbrun LK, Ruckdeschel JD: A phase II trial of pemetrexed (P), gemcitabine (G), and bevacizumab (BV) in untreated patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):e19099

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of pemetrexed (P), gemcitabine (G), and bevacizumab (BV) in untreated patients (pts) with advanced non-small cell lung cancer (NSCLC).
  • : e19099 Background: P and G are active agents with acceptable toxicity profiles in the treatment of NSCLC.
  • The addition of BV to chemotherapy has resulted in a significant improvement in survival for pts with non-squamous NSCLC.
  • METHODS: Advanced, non-squamous NSCLC pts with measurable/evaluable disease, no prior treatment for advanced disease, PS 0-1, adequate hepatic, renal and bone marrow function, treated brain metastases were eligible.
  • Secondary endpoints are response rate (RR), toxicity, time to progression and overall survival.
  • Median age 57.5 yrs, males-55%, stage IV 90%, adenocarcinoma 75%.
  • Currently the median treatment cycles for all pts are 6 (range 1-12).
  • CONCLUSIONS: The combination of P, G, and BV is a very active and tolerable treatment for NSCLC despite the preliminary nature of these results.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962253.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Villanueva N, Esteban E, Fra J, De Sande J, Mareque B, Uña E, Muñiz I, Fernández Y, Buesa J, Lacave A: Cisplatin plus gemcitabine with or without vinorelbine as neoadjuvant therapy for radically treatable stage III non small cell lung cancer (NSCLC). Preliminary results of a randomised study of the GON (Grupo Oncológico del Norte de España). J Clin Oncol; 2004 Jul 15;22(14_suppl):7171

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cisplatin plus gemcitabine with or without vinorelbine as neoadjuvant therapy for radically treatable stage III non small cell lung cancer (NSCLC). Preliminary results of a randomised study of the GON (Grupo Oncológico del Norte de España).
  • : 7171 Background: The combinations of cisplatin (C) with gemcitabine (G) and/or vinorelbine (V) have shown to be effective and safe regimens in the first line treatment of NSCLC.This study was conducted to determine whether the association of V to the combination of CG (VCG) increases the efficacy and not the toxicity when compared to CG administered as neoadjuvant therapy in patients with radically-treatable stage III NSCLC.
  • METHODS: Patients (pts) ≤ 75 years old, Karnofsky index ≥ 70% and adequate haematological, renal and hepatic function are stratified by stage (IIIA versus IIIB) and randomly assigned to: C 50 mg/m<sup>2</sup> i.v. and G 1250 mg/m<sup>2</sup> i.v. d1 and d8 alone (CG) or in combination with V 25 mg/m <sup>2</sup> i.v. d1 and d8 (VCG) both regimens every 3 weeks for 3 consecutive cycles followed by definitive local treatment (LT).
  • From December 1999 to December 2003, a Hundred and fifteen pts have been randomised and evaluated (CG/VCG); median age 57/58; median Karnofsky index 80/80; stage IIIA 19/21; stage IIIB 39/36; adenocarcinoma 27/27; squamous 26/26; anaplastic 5/4.
  • RESULTS: [Figure: see text] Five pts in CG and 6 in VCG arm developed progression disease during induction treatment with chemotherapy.
  • Two pts in both arms developed neutropenic fever.
  • CONCLUSIONS: Preliminary results show similar high efficacy associated with moderate toxicity in both groups of treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014285.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Niho S, Kubota K, Goto K, Yoh K, Ohmatsu H, Kakinuma R, Nishiwaki Y: First-line single agent of gefitinib in patients (pts) with advanced non-small cell lung cancer (NSCLC): A phase II study. J Clin Oncol; 2004 Jul 15;22(14_suppl):7059

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First-line single agent of gefitinib in patients (pts) with advanced non-small cell lung cancer (NSCLC): A phase II study.
  • : 7059 Background: Gefitinib is active for recurrent NSCLC after platinum-based chemotherapy (Fukuoka M, et al.
  • However, efficacy of gefitinib as first-line chemotherapy remains unknown.
  • METHODS: Eligibility criteria: stage IIIB (malignant pleural or pericardial effusion and/or metastasis in the same lobe) or IV NSCLC without previous chemotherapy, measurable lesion, 20≤age≤74, ECOG PS 0 or 1, PaO<sub>2</sub>≥60 torr, and adequate bone marrow, renal, and hepatic functions.
  • TREATMENT: Pts received 250mg doses of gefitinib every day.
  • In these cases, platinum-based doublet chemotherapy was performed as salvage.
  • Patient characteristics: male/female = 24/13, median age = 61 (range 44-74), ECOG PS 0/1 = 14/23, stage IIIB/IV = 3/34, and adenocarcinoma / squamous / large cell = 27/3/7.
  • Four pts developed grade 5 interstitial lung disease (ILD).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016113.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Nagao S, Fujiwara K, Oda T, Ishikawa H, Koike H, Tanaka H, Kohno I: Docetaxel and carboplatin combination chemotherapy in advanced or recurrent cervix cancer of the uterus. A pilot study. J Clin Oncol; 2004 Jul 15;22(14_suppl):5099

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Docetaxel and carboplatin combination chemotherapy in advanced or recurrent cervix cancer of the uterus. A pilot study.
  • : 5099 Background: This is a pilot study to assess an efficacy and safety of combination chemotherapy of docetaxel and carboplatin in advanced or recurrent uterine cervix cancer for the future trial.
  • METHODS: The patients eligible for this study were those who were histologically confirmed (squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma), advanced (stage IB2-IV) or recurrent uterine cervix cancer.The patient must have measurable lesion and must have sufficient bone marrow, renal, and liver function.
  • Chemotherapy was repeated 1-6 courses depending on the purpose of the therapy.
  • However, confirmation of the objective response no less than 4 weeks after criteria for response are first met was not required in patients who underwent chemotherapy as a neoadjuvant setting.
  • Distribution of stage was IB2; 1, IIB; 6, IIIB; 2, IVB; 2, Recurrent; 2.
  • There were 6 squamous cell carcinomas, 5 adenocarcinomas and 1 adenosquamous cell carcinoma.
  • All 5 adenocarcinoma patients under neoadjuvant chemotherapy setting responded including 1 pathological CR.
  • CONCLUSIONS: Combination of docetaxel and carboplatin is effective and safe treatment for uterine cervix cancer.
  • Further evaluation particularly targeted on cervical adenocarcinoma is warranted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015322.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Cheong KA, Chrystal K, Forshaw M, Gossage J, Galani E, Botha A, Mason R, Harper PG: Neoadjuvant chemotherapy in "technically" inoperable locally advanced oesophageal (O) and gastro-oesophageal junction (GOJ) cancer. J Clin Oncol; 2004 Jul 15;22(14_suppl):4138

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy in "technically" inoperable locally advanced oesophageal (O) and gastro-oesophageal junction (GOJ) cancer.
  • For this group we routinely use 3 cycles of neoadjuvant ECF-based chemotherapy (Epirubicin:60mg/m<sup>2</sup>, Cisplatin:60mg/m<sup>2</sup>, 5FU 200mg/m<sup>2</sup> CIVI q21).
  • All patients commencing chemotherapy were included.
  • Chemotherapy variations depended on comorbidities and renal function.
  • HISTOLOGY: adenocarcinoma 80%, squamous cell 20%.
  • Stage at presentation: T3/T4N0 17%, T3/T4N1 58%, and T3/T4N1M1a 25%.
  • Chemotherapy regimen: ECF 73%, ECSF 10%, ECarboF 10%, CF 7%.
  • 85% of patients completed a minimum of 3 cycles of neoadjuvant chemotherapy.
  • 18 pts had further adjuvant therapy (34% chemo, 7% chemoradiation, 2% radiation).
  • CONCLUSIONS: Surgery following successful neoadjuvant chemotherapy for initially inoperable locally advanced O and GOJ cancer can produce encouraging survival rates.
  • Prospective studies, including identification of prognostic and predictive factors for response to chemotherapy are required.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014551.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Martoni A, Di Fabio F, Guaraldi M, Piana E, Ramini R, Lelli G, Palomba G, Artioli F, Bandieri E, Robustelli Della Cuna G, Preti P: Prospective phase II study of single-agent gemcitabine in untreated elderly patients with stage IIIB/IV non-small-cell lung cancer. Am J Clin Oncol; 2001 Dec;24(6):614-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective phase II study of single-agent gemcitabine in untreated elderly patients with stage IIIB/IV non-small-cell lung cancer.
  • The purpose of this study was to evaluate the efficacy and tolerability of single-agent gemcitabine in untreated elderly patients with stage IIIb/IV non-small-cell lung cancer (NSCLC).
  • Primary patient characteristics were: male/female 38/8; median age 73 years (range: 70-82 years); median Karnofsky performance status (PS) 90 (range: 70-100); stage IIIb 61% and stage IV 39%; histotype: epidermoid 48%, adenocarcinoma 43%, and large cell carcinoma 9%.
  • The median time to progression was 4 months, the median survival was 9 months, and 1-year survival was 44%.
  • Grade I/II side effects of nausea/vomiting, transient fever, increase of hepatic transaminases, transient peripheral edema at lower extremity (not related to cardiac or renal disease or phlebothrombosis) were reported.
  • This phase II study confirms the activity and favorable toxicity profile of single-agent gemcitabine in the treatment of elderly patients with advanced NSCLC.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11801766.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


28. Kolh P, Honore P, Degauque C, Gielen J, Gerard P, Jacquet N: Early stage results after oesophageal resection for malignancy - colon interposition vs. gastric pull-up. Eur J Cardiothorac Surg; 2000 Sep;18(3):293-300
ORBi (University of Liege). Free full Text at ORBi .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early stage results after oesophageal resection for malignancy - colon interposition vs. gastric pull-up.
  • Indications were squamous cell carcinoma in 69 patients and adenocarcinoma in 61.
  • Preoperatively 30 patients (eight in stage IIB, 18 in stage III, and four in stage IV) received radiochemotherapy.
  • There were 84 subtotal oesophagectomies, with anastomosis in the neck in 44 patients and at the thoracic inlet in 40, and 46 distal oesophageal resections.
  • Postoperative complications occurred in 40 patients (31%), respectively, in ten (26%) and 30 (33%) patients after colonic and gastric transplants (P=0.48), and were pulmonary insufficiency or infection in 29 patients, anastomotic fistula in six, myocardial infarction in five, recurrent nerve palsy in four, renal insufficiency in three, and cerebrovascular accident in one.
  • The incidence of postoperative pulmonary complications was 70% (21/30 patients) in the subgroup who received preoperative radiochemotherapy, as compared to 11% (5/44 patients) in the subgroup of comparable staging, but without preoperative treatment (P<0.001).
  • Our results suggest that preoperative neoadjuvant treatment significantly increases postoperative pulmonary complications.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Colon / transplantation. Esophageal Neoplasms / surgery. Esophagus / surgery. Stomach / surgery
  • [MeSH-minor] Anastomosis, Surgical / methods. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophagectomy. Female. Hospital Mortality. Humans. Male. Middle Aged. Palliative Care. Reoperation. Retrospective Studies. Stomach Neoplasms / drug therapy. Stomach Neoplasms / mortality. Stomach Neoplasms / radiotherapy. Stomach Neoplasms / surgery. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10973538.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] ENGLAND
  •  go-up   go-down


29. Kaira K, Tsuchiya S, Sunaga N, Yanagitani N, Watanabe S, Imai H, Hisada T, Ishizuka T, Saito R, Mori M: A phase I dose escalation study of weekly docetaxel and carboplatin in elderly patients with nonsmall cell lung cancer. Am J Clin Oncol; 2007 Feb;30(1):51-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I dose escalation study of weekly docetaxel and carboplatin in elderly patients with nonsmall cell lung cancer.
  • OBJECTIVE: We conducted a phase I dose escalation study to determine the maximum tolerated dose (MTD), the recommended dose (RD), and the safety profile of a weekly docetaxel and carboplatin combination regimen in the treatment of elderly patients with advanced nonsmall cell lung cancer (NSCLC).
  • PATIENTS AND METHODS: Chemotherapy-naive patients with stage IIIB and IV NSCLC, >70 years of age, performance status (ECOG) 0-2, with adequate bone marrow, renal, liver and cardiac function, were treated with docetaxel and carboplatin.
  • The dose limiting toxicity (DLT) of the regimen was assessed during the first chemotherapy cycle.
  • Nonhematologic toxicities were generally mild, and included grade 3 constipation in 1 patient (4%) and grade 3 renal disorder in 1 patient (4%).
  • The combination of docetaxel and carboplatin is a feasible and well-tolerated regimen for the treatment of elderly patients with advanced NSCLC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / toxicity. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Aged. Aged, 80 and over. Carboplatin / administration & dosage. Carcinoma, Large Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Male. Neoplasm Staging. Taxoids / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17278895.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin
  •  go-up   go-down


30. Mylonakis N, Athanasiou A, Ziras N, Angel J, Rapti A, Lampaki S, Politis N, Karanikas C, Kosmas C: Phase II study of liposomal cisplatin (Lipoplatin) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer. Lung Cancer; 2010 May;68(2):240-7
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of liposomal cisplatin (Lipoplatin) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer.
  • In the present randomized phase II study, we examined the efficacy and safety of a Lipoplatin-gemcitabine versus a cisplatin-gemcitabine combination as first line treatment in advanced NSCLC.
  • Efficacy was assessed in patients who completed at least 1 cycle of treatment; ORR was 31.7% in arm A versus 25.6% in arm B and DCR was 70.7% versus 56.4%, respectively.
  • A preliminary efficacy of LipoGem versus CisGem in the adenocarcinoma histological subtype of NSCLC showed 16.7% versus 45.8% PD.
  • Treatment in arm A was better tolerated with myelotoxicity and a transient mild elevation of serum creatinine as the dominant side effects; the only grade 4 adverse event was neutropenia noted in 2% of the patients.
  • CONCLUSION: Overall, Lipoplatin appears to have lower toxicity, mainly renal toxicity as well as higher efficacy than cisplatin when combined with gemcitabine in advanced NSCLC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Cisplatin / administration & dosage. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19628292.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / lipoplatin; 0W860991D6 / Deoxycytidine; AYI8EX34EU / Creatinine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


31. Kosmas C, Tsavaris NB, Polyzos A, Kalofonos HP, Sepsas E, Malamos NA, Vadiaka M, Dosios T, Antonopoulos MJ: A phase II study of paclitaxel-ifosfamide-cisplatin combination in advanced nonsmall cell lung carcinoma. Cancer; 2000 Aug 15;89(4):774-82
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of paclitaxel-ifosfamide-cisplatin combination in advanced nonsmall cell lung carcinoma.
  • BACKGROUND: The necessity to develop more effective chemotherapy regimens in advanced nonsmall cell lung carcinoma (NSCLC) prompted the authors to evaluate the paclitaxel-ifosfamide-cisplatin (PIC) combination, developed on the basis of high individual single-agent activity, in vitro synergism, and tolerance as determined in a previous Phase I study by the authors.
  • PATIENTS: Eligibility criteria included advanced NSCLC (American Joint Committee on Cancer [AJCC]/International Union Against Cancer [UICC] Stage III/IV), Eastern Cooperative Oncology Group performance status (PS) </= 2, no prior chemotherapy, and unimpaired hematopoietic and organ function.
  • Chemotherapy included, paclitaxel 175 (in the first 10 patients) or 200 mg/m(2) on Day 1, ifosfamide: 5 g/m(2) divided over Days 1 and 2, and cisplatin 100 mg/m(2) divided over Days 1 and 2, recycled every 21 days.
  • RESULTS: Fifty patients were entered, and all were evaluable for response and toxicity: median age, 58 years (range, 40-72), PS, 1 (range, 0-2), Gender: 44 males and 6 females, Stages IIIA, 6 patients; IIIB, 17; IV, 27; histologies: adenocarcinoma, 27 patients; squamous, 17; large cells, 5; unspecified, 1.
  • The median response duration was 7 months (range 2-34+); median time-to-progression, 8 months (range, 1-36+), median overall survival, 12 months (range, 2-36+).
  • Grade 3 and 4 toxicities included neutropenia 38 of 50 patients with 21 developing Grade 4 neutropenia (</= 5 days) and 7 of these febrile neutropenia (14%); thrombocytopenia, 4 of 50 patients with 1 Grade 4 requiring platelet transfusions, 1 Grade 3 neuropathy; Grade 1-2 central nervous system toxicity due to ifosfamide was seen in 22 patients, no renal toxicity, 15 Grade 2 myalgias, 17 Grade 2 diarrhea, and 10 Grade 3 vomiting.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Cisplatin / adverse effects. Female. Humans. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. Male. Middle Aged. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Patient Compliance. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 American Cancer Society.
  • (PMID = 10951340.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


32. Hermida Pérez JA, Del Corral Suarez T, Cerdeiras Martínez G, Ochoa Undargarain O: [Hypernephroma associated with primary bladder tumor. Report of a case]. Arch Esp Urol; 2000 Mar;53(2):174-6
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Hipernefroma asociado a tumor primitivo vesical. Presentación de un caso.
  • OBJECTIVE: To present a case of tubular renal adenocarcinoma associated with transitional cell carcinoma of the bladder.
  • METHODS/RESULTS: A case of tubular renal adenocarcinoma associated with transitional cell carcinoma of the bladder in a 42-year-old patient is described.
  • Patient evaluation included intravenous urography, nephrotomograms, renal and bladder ultrasound evaluation and cystoscopic examination with biopsy.
  • The patient underwent nephroureterectomy and partial cystectomy with subsequent radiotherapy and intravesical chemotherapy.
  • CONCLUSIONS: The appearance of various early-stage urological tumors in the same patient, is uncommon.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Renal Cell / diagnosis. Carcinoma, Transitional Cell / diagnosis. Kidney Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis. Urinary Bladder Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10802926.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] SPAIN
  • [Number-of-references] 14
  •  go-up   go-down


33. Zarogoulidis K, Kontakiotis T, Hatziapostolou P, Fachantidou E, Delis D, Goutsikas J, Constantinidis TC, Athanasiadis A, Patakas D: A Phase II study of docetaxel and carboplatin in the treatment of non-small cell lung cancer. Lung Cancer; 2001 Jun;32(3):281-7
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Phase II study of docetaxel and carboplatin in the treatment of non-small cell lung cancer.
  • We investigated the efficacy of docetaxel (D) in combination with carboplatin (C) in the treatment of non-small cell lung cancer (NSCLC) patients.
  • Of those, 46 patients had squamous carcinoma, 44 adenocarcinoma, 11 large cell carcinoma and 19 undifferentiated tumours.
  • Eligibility criteria included, documented inoperable NSCLC, WHO performance status (PS) 0-1, age up to 70 years, and normal renal and hepatic function.
  • A total of 622 cycles of chemotherapy (CHT) (median 7 (95% CI 6.2-7.47), courses per patient) were administered.
  • Each cycle consisted of 100 mg/m(2) of docetaxel in a 2-h infusion with C at a dose of area under the curve (AUC) of 6 on day 1.
  • The median survival was 12 months for all patients, 12 for the four patients with stage IIb disease, 18 for the patients with stage IIIa disease, 20 for the 29 patients with stage IIIb disease, and 11 for the 65 stage IV patients.
  • The median time to progression was 8 months (90 patients).
  • Responders received radiotherapy (total dose, 50 Gy in 4 weeks) between the 6th and 8th cycle.
  • Among responders with initial stage IIIb disease, 7 (5%) underwent surgical resection.
  • Preliminary results indicate that the D/C combination is very active in the treatment of NSCLC with tolerable toxicity.
  • It appears that this drug combination is also good as neoadjuvant therapy in inoperable NSCLC patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Paclitaxel / analogs & derivatives. Taxoids
  • [MeSH-minor] Adult. Aged. Anemia / chemically induced. Carboplatin / administration & dosage. Disease Progression. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neutropenia / chemically induced. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11390009.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


34. Rubio JC, Vázquez S, Vázquez F, Amenedo M, Fírvida JL, Mel JR, Huidobro G, Alvarez E, Lázaro M, Alonso G, Fernández I, Galician Group of Lung Cancer (GGCP in the Spanish acronym): A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma. Cancer Chemother Pharmacol; 2009 Jul;64(2):379-84
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma.
  • PURPOSE: To test efficacy and tolerability of non-platinum regimens for advanced non-small-cell lung cancer (NSCLC).
  • METHODS: Chemonaive patients with measurable stage IIIB/IV NSCLC treated with gemcitabine and cisplatin (GC), or gemcitabine and docetaxel (GD), maximumsix cycles in a phase IIB trial.
  • Median Overall Survival (OS): 8.9 months in both groups (P = 0.53); and median time to progression (TTP): 6.2/5.5 months respectively (P = 0.61).
  • Non-haematological toxicity was similar, except for nausea and vomiting, (16.3/2%); renal toxicity (3.7/0%) and hepatic toxicity (5.6/12.7%).
  • CONCLUSIONS: With a higher overall response rate and lower toxicity, GD is a good first treatment option for advanced NSCLC.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Large Cell / drug therapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Humans. Male. Middle Aged. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Prognosis. Survival Rate. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19139896.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


35. Adachi S, Ogasawara T, Tsubamoto H, Oku H, Hori Y, Tsuji Y, Takemura T, Koyama K: Intravenous nedaplatin and intraarterial cisplatin with transcatheter arterial embolization for patients with locally advanced uterine cervical cancer. Int J Clin Pharmacol Res; 2001;21(3-4):105-10
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nedaplatin is a platinum analog that has less renal toxicity and higher efficacy for uterine cervical cancer than cisplatin.
  • Intraarterial cisplatin has been shown to be more effective than intravenous cisplatin in the treatment of cervical cancer.
  • To improve the prognosis of cervical cancer, we studied combination chemotherapy of intravenous nedaplatin and intraarticular cisplatin with transcatheter arterial embolization (TAE).
  • The criteria for selecting patients for this study were as follows: age 16-75 years, stage Ib2-IV according to the classification of the International Federation of Gynecology and Obstetrics (FIGO), performance status between 0 and 2, a creatinine clearance of >40 ml/min, adequate bone marrow and adequate renal and hepatic function.
  • FIGO stage was Ib2 in seven patients, IIa in seven patients, IIb in four, IIIa in one, IIIb in seven and IVa in six.
  • Twenty-four patients had squamous cell carcinoma, three had adenocarcinoma and five had adenosquamous carcinoma.
  • This course of treatment was repeated every 3 weeks for 2-3 cycles.
  • Response to the therapy was defined by magnetic resonance imaging.
  • These results show that this combination chemotherapy effected a high response rate.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Balloon Occlusion / methods. Cisplatin / administration & dosage. Organoplatinum Compounds / administration & dosage. Uterine Cervical Neoplasms / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adult. Aged. Antineoplastic Agents / administration & dosage. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / mortality. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Female. Follow-Up Studies. Humans. Infusions, Intra-Arterial. Infusions, Intravenous. Middle Aged. Survival Rate

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12067139.001).
  • [ISSN] 0251-1649
  • [Journal-full-title] International journal of clinical pharmacology research
  • [ISO-abbreviation] Int J Clin Pharmacol Res
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


36. Niibe Y, Tsunoda S, Jobo T, Imai M, Matsuo K, Matsunaga K, Unno N, Hayakawa K: Phase II study of radiation therapy combined with weekly nedaplatin in locally advanced uterine cervical carcinoma (LAUCC): Kitasato Gynecologic Radiation Oncology Group (KGROG 0501)--initial analysis. Eur J Gynaecol Oncol; 2008;29(3):222-4
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of radiation therapy combined with weekly nedaplatin in locally advanced uterine cervical carcinoma (LAUCC): Kitasato Gynecologic Radiation Oncology Group (KGROG 0501)--initial analysis.
  • OBJECTIVE: Locally advanced uterine cervical carcinoma (LAUCC) treated with chemoradiotherapy is considered to be the standard treatment regimen.
  • Furthermore, the total dose of Japanese radiation therapy protocol is less than that of the USA which indicated that chemoradiotherapy for LAUCC is better than radiation therapy alone by phase III clinical trials.
  • Thus, the current phase II study was designed to evaluate chemoradiotherapy with a lower radiation dose for LAUCC using weekly nedaplatin effectively and safely in the Japanese population.
  • Nedaplatin is a platinum drug and no hydration is required to infuse patients because it is less toxic on renal function.
  • PATIENTS AND METHODS: Patients registered in the current study were found to have LAUCC based on the following criteria i) pathologically proven squamous cell carcinoma or adenocarcinoma, ii) FIGO clinical Stage Ib, IIa, IIb with bulky tumor (diameter > 40 mm assessed by pelvic magnetic resonance imaging) or pelvic lymph node swelling (diameter > 10 mm assessed by pelvic computed tomography);.
  • iii) FIGO clinical Stage IIIa, IIIb and IVa with no paraaortic lymph node swelling (diameter > 10 mm) observed by abdominal computed tomography;.
  • The treatment protocol was as follows: Radiation therapy in a combination of external beam radiation therapy (total dose: 50 Gy-52 Gy/25-27 fractions with central shielding after 30-32 Gy) with high-dose rate intracavitary irradiation (24-30 Gy/4-6 fractions to point A).
  • Chemotherapy applied in the current study was weekly nedaplatin infused intravenously (30 mg/mm2/time, once a week, total 150 mg/mm2/5 weeks).
  • As for clinical stage, nine were IIIb and only one was IIb.
  • Nine patients were proven to have squamous cell carcinoma and one adenocarcinoma.
  • [MeSH-major] Adenocarcinoma. Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell. Organoplatinum Compounds / therapeutic use. Uterine Cervical Neoplasms

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18592783.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin
  •  go-up   go-down


37. Grande M, Facchini F, La Rosa M, Pozzoli GL, Leone M, Piana S, Monica B: [Carcinoma of the collecting ducts of Bellini: a case report with cutaneous metastasis as the initial clinical manifestation]. Urologia; 2010 Jan-Mar;77 Suppl 16:51-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Bellini's collecting ducts carcinoma represents a rare tumor with an aggressive behaviour with a poor prognosis and often metastatic at diagnosis.
  • MATERIALS AND METHODS: All pertinent clinical information were compiled, including patient age, sex, mode of presentation, preoperative laboratory data, radiologic findings, surgery type, macro and microscopic findings, survival data.
  • RESULTS: After reporting an histopathologic finding of cutaneous metastasis of unknown origin adenocarcinoma with poorly differentiation, a voluminous 6 cm left mesorenal mass is diagnosed through uro-CT.
  • The histopathologic diagnosis reported was Bellini tumor at stage pT3a-N2-M1.
  • It has not reported significative responsiveness to adjuvant chemotherapy and the patient was died seven months after diagnosis of cutaneous metastasis.
  • In this context, radical nephrectomy, differently from others subtypes of advanced renal cell carcinoma, does not seem to improve survival of the patient but rather, it can keep a role in palliation or in the context of new chemotherapeutic protocols.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Kidney Neoplasms / diagnosis. Skin Neoplasms / secondary
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Combined Modality Therapy. Fatal Outcome. Humans. Lymphatic Metastasis. Male. Neoplasm Staging. Nephrectomy. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21104663.001).
  • [ISSN] 1724-6075
  • [Journal-full-title] Urologia
  • [ISO-abbreviation] Urologia
  • [Language] ita
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Madroszyk-Flandin A, Bagattini S, Gonçalves A, Salem N, Viret F, Viallat JR, Rousseau F, Protière C, Bertucci F, Maraninchi D, Viens P: Lung cancer in elderly patients: a retrospective analysis of practice in a single institution. Crit Rev Oncol Hematol; 2007 Oct;64(1):43-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Incidence of non-small cell lung cancer is increasing especially among elderly with about 40% arising in patients over 70 years old.
  • Comorbidities were represented by arterial hypertension, coronaropathy, cardiac failure, thrombo-embolism, respiratory failure, diabetes, vascular cerebral dysfunction, and renal failure.
  • Histological characteristics: epidermoïd/adenocarcinoma/undifferentiated/small cells: 39.4%/26.8%/15.5%/9.9%.
  • Most of them were advanced lung cancer: St IIIB=14 (19.7%) and St IV=37 (52.1%).
  • Forty-six patients received chemotherapy (64.8%) with 40 patients (86.9%) with platin (carboplatin or cisplatin).
  • The median number of treatment cycles was 4.1 (range 1-7).
  • The 1-year survival rate was 48.5% and the estimated median survival time was 11 months (95%; 7-18 months) for all patients.
  • The 1-year survival rate was 75% and 21.6% and the estimated median survival time was 25.9 months (95%; 12.6, ND) and 5.7 months (95%; 4.2-9.6) for stage IIIB and IV, respectively.
  • Toxicities were judged acceptable with 19 hospitalizations after chemotherapy, for 16 patients who represent 34.8% of patients who received chemotherapy.
  • CONCLUSIONS: Chemotherapy is feasible in elderly patients with lung cancer.
  • Patients should be evaluated for chemotherapy based on their performance status and comorbidities especially with geriatric assessment rather than age alone.
  • The chemotherapy with platinum seems to be tolerable and effective.
  • [MeSH-major] Lung Neoplasms / drug therapy. Lung Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17826629.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


39. Rice DC, Correa AM, Vaporciyan AA, Sodhi N, Smythe WR, Swisher SG, Walsh GL, Putnam JB Jr, Komaki R, Ajani JA, Roth JA: Preoperative chemoradiotherapy prior to esophagectomy in elderly patients is not associated with increased morbidity. Ann Thorac Surg; 2005 Feb;79(2):391-7; discussionn 391-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Preoperative chemotherapy and radiation therapy are often administered to patients with esophageal cancer.
  • Despite an aging population, little data exist regarding feasibility of preoperative therapy in elderly patients.
  • Outcomes of patients 70 years old, who underwent preoperative therapy (n = 35; group II), were compared with those of patients who did not (n = 39; group I) and with those of patients younger than 70 years old who received preoperative therapy (n = 165; group III).
  • The patients in group II were of more advanced clinical stage (p < 0.001).
  • CONCLUSIONS: Elderly patients receiving preoperative therapy for esophageal cancer do not have an increased incidence of major postoperative complications.
  • Elderly patients receiving preoperative therapy are more likely to develop postoperative atrial arrhythmias and require transfusion than younger patients.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / epidemiology. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Age Factors. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Awards and Prizes. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Cardiovascular Diseases / epidemiology. Chemotherapy, Adjuvant. Comorbidity. Diabetes Mellitus, Type 1 / epidemiology. Female. Follow-Up Studies. Humans. Length of Stay / statistics & numerical data. Male. Multivariate Analysis. Neoplasm Staging. Pulmonary Disease, Chronic Obstructive / epidemiology. Radiotherapy, Adjuvant. Renal Insufficiency / epidemiology. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15680801.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


40. Busby JE, Brown GA, Tamboli P, Kamat AM, Dinney CP, Grossman HB, Matin SF: Upper urinary tract tumors with nontransitional histology: a single-center experience. Urology; 2006 Mar;67(3):518-23
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We reviewed the patient records to collect data on tumor subtype, treatment, recurrence, and survival.
  • RESULTS: Sixteen patients (1.9% of our database of patients with upper urinary tract tumors) were identified; 12 had squamous cell carcinoma, 2 had adenocarcinoma, 1 had sarcomatoid carcinoma, and 1 had small cell carcinoma.
  • The tumors were located in the renal pelvis in 10 and the ureter in 6.
  • Of the 16 patients, 15 had been treated with nephrectomy or nephrouterectomy and 1 with chemotherapy and radiotherapy.
  • Fifteen of the tumors were pathologic Stage T3 or worse.
  • Ten patients received adjuvant chemotherapy.
  • The median follow-up was 30.1 months, the median overall survival time was 11.3 months, and 1-year survival rate was 46%.
  • The median recurrence-free survival time and 1-year recurrence-free survival rate were 5.8 months and 38%, respectively.
  • CONCLUSIONS: Primary nonurothelial carcinomas of the renal pelvis and ureter are rare.
  • Our analysis suggests a poor prognosis for most patients with these pathologic types, probably resulting from the advanced stage at diagnosis and poor responses to systemic therapy.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16527570.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA79449; United States / NCI NIH HHS / CA / CA91846
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


41. Andreev OA, Dupuy AD, Segala M, Sandugu S, Serra DA, Chichester CO, Engelman DM, Reshetnyak YK: Mechanism and uses of a membrane peptide that targets tumors and other acidic tissues in vivo. Proc Natl Acad Sci U S A; 2007 May 8;104(19):7893-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mechanism and uses of a membrane peptide that targets tumors and other acidic tissues in vivo.
  • The pH-selective insertion and folding of a membrane peptide, pHLIP [pH (low) insertion peptide], can be used to target acidic tissue in vivo, including acidic foci in tumors, kidneys, and inflammatory sites.
  • In a mouse breast adenocarcinoma model, fluorescently labeled pHLIP finds solid acidic tumors with high accuracy and accumulates in them even at a very early stage of tumor development.
  • The fluorescence signal is stable for >4 days and is approximately five times higher in tumors than in healthy counterpart tissue.
  • In a rat antigen-induced arthritis model, pHLIP preferentially accumulates in inflammatory foci. pHLIP also maps the renal cortical interstitium; however, kidney accumulation can be reduced significantly by providing mice with bicarbonate-containing drinking water.
  • At physiological pH, the equilibrium is toward water, which explains its low affinity for cells in healthy tissue; at acidic pH, titration of Asp residues shifts the equilibrium toward membrane insertion and tissue accumulation.
  • The replacement of two key Asp residues located in the transmembrane part of pHLIP by Lys or Asn led to the loss of pH-sensitive insertion into membranes of liposomes, red blood cells, and cancer cells in vivo, as well as to the loss of specific accumulation in tumors. pHLIP nanotechnology introduces a new method of detecting, targeting, and possibly treating acidic diseased tissue by using the selective insertion and folding of membrane peptides.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Physiol. 1996 Jul;271(1 Pt 2):F132-42 [8760254.001]
  • [Cites] Biophys J. 1981 Oct;36(1):1-19 [7284547.001]
  • [Cites] J Rheumatol. 1998 Sep;25(9):1772-7 [9733459.001]
  • [Cites] J Rheumatol. 1999 Sep;26(9):2018-24 [10493685.001]
  • [Cites] Cardiology. 2005;103(1):10-6 [15528895.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 21;101(51):17867-72 [15601762.001]
  • [Cites] Curr Med Chem. 2005;12(7):795-805 [15853712.001]
  • [Cites] Nature. 2006 Jan 19;439(7074):353-7 [16273092.001]
  • [Cites] Mol Cancer Res. 2006 Feb;4(2):61-70 [16513837.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6460-5 [16608910.001]
  • [Cites] Science. 2006 May 26;312(5777):1168-71 [16728630.001]
  • [Cites] JAMA. 2006 Jul 26;296(4):445-8 [16868303.001]
  • [Cites] Nature. 2006 Jul 27;442(7101):461-5 [16688182.001]
  • [Cites] Med Chem. 2006 May;2(3):315-27 [16948479.001]
  • [Cites] Cell Oncol. 2006;28(4):127-39 [16988468.001]
  • [Cites] Arthritis Rheum. 2007 Jan;56(1):108-16 [17195213.001]
  • [Cites] Mol Med Today. 2000 Jan;6(1):15-9 [10637570.001]
  • [Cites] Biophys J. 2001 Sep;81(3):1735-58 [11509384.001]
  • [Cites] J Appl Toxicol. 2001 Nov-Dec;21(6):513-9 [11746200.001]
  • [Cites] Atherosclerosis. 2002 Sep;164(1):27-35 [12119190.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16766-9 [12471152.001]
  • [Cites] Cancer Treat Rev. 2003 Dec;29(6):541-9 [14585264.001]
  • [Cites] Cell. 2004 Sep 17;118(6):665-6 [15369664.001]
  • [Cites] Cell. 2004 Sep 17;118(6):687-98 [15369669.001]
  • [Cites] Crit Care. 2004 Oct;8(5):331-6 [15469594.001]
  • [Cites] Proc Natl Acad Sci U S A. 1974 Nov;71(11):4457-61 [4530994.001]
  • [Cites] Biochemistry. 1997 Dec 9;36(49):15177-92 [9398245.001]
  • (PMID = 17483464.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM070895; United States / NCRR NIH HHS / RR / P20 RR016457; United States / NIGMS NIH HHS / GM / GM073857; United States / NCRR NIH HHS / RR / P20RR016457; United States / NIGMS NIH HHS / GM / GM070895; United States / NIGMS NIH HHS / GM / R01 GM073857
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Lipid Bilayers; 0 / Membrane Proteins
  • [Other-IDs] NLM/ PMC1861852
  •  go-up   go-down






Advertisement